

# Janet M Siliciano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/819281/publications.pdf>

Version: 2024-02-01

67  
papers

12,743  
citations

81743

39  
h-index

110170

64  
g-index

70  
all docs

70  
docs citations

70  
times ranked

6630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. <i>Nature Medicine</i> , 1999, 5, 512-517.	15.2	1,962
2	Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. <i>Nature Medicine</i> , 2003, 9, 727-728.	15.2	1,482
3	Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure. <i>Cell</i> , 2013, 155, 540-551.	13.5	1,207
4	Defective proviruses rapidly accumulate during acute HIV-1 infection. <i>Nature Medicine</i> , 2016, 22, 1043-1049.	15.2	605
5	Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. <i>PLoS Pathogens</i> , 2013, 9, e1003174.	2.1	524
6	A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. <i>Nature</i> , 2019, 566, 120-125.	13.7	471
7	Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. <i>Nature</i> , 2015, 517, 381-385.	13.7	469
8	New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. <i>Nature Medicine</i> , 2014, 20, 425-429.	15.2	436
9	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016, 22, 839-850.	15.2	395
10	HIV-1 Integration Landscape during Latent and Active Infection. <i>Cell</i> , 2015, 160, 420-432.	13.5	393
11	Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 + T Cells. <i>Journal of Virology</i> , 2006, 80, 6441-6457.	1.5	377
12	Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. <i>Journal of Experimental Medicine</i> , 2017, 214, 959-972.	4.2	327
13	Resting CD4 + T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes. <i>Journal of Virology</i> , 2004, 78, 6122-6133.	1.5	306
14	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. <i>Nature</i> , 2020, 585, 261-267.	13.7	245
15	Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay. <i>PLoS Pathogens</i> , 2013, 9, e1003398.	2.1	228
16	Enhanced Culture Assay for Detection and Quantitation of Latently Infected, Resting CD4<sup>+</sup> T-Cells Carrying Replication-Competent Virus in HIV-1-Infected Individuals. , 2005, 304, 003-016.		216
17	Orientation-Dependent Regulation of Integrated HIV-1 Expression by Host Gene Transcriptional Readthrough. <i>Cell Host and Microbe</i> , 2008, 4, 134-146.	5.1	190
18	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. <i>PLoS Medicine</i> , 2017, 14, e1002417.	3.9	186

#	ARTICLE	IF	CITATIONS
19	Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2575-E2584.	3.3	173
20	Stability of the Latent Reservoir for HIV-1 in Patients Receiving Valproic Acid. Journal of Infectious Diseases, 2007, 195, 833-836.	1.9	169
21	Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection. Immunity, 2017, 47, 766-775.e3.	6.6	160
22	Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. JCI Insight, 2020, 5, .	2.3	140
23	Characterization of Chemokine Receptor Utilization of Viruses in the Latent Reservoir for Human Immunodeficiency Virus Type 1. Journal of Virology, 2000, 74, 7824-7833.	1.5	139
24	Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1. Open Forum Infectious Diseases, 2015, 2, ofv123.	0.4	119
25	Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo. Journal of Clinical Investigation, 2021, 131, .	3.9	103
26	Influence of Host Gene Transcription Level and Orientation on HIV-1 Latency in a Primary-Cell Model. Journal of Virology, 2011, 85, 5384-5393.	1.5	102
27	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	15.2	96
28	Measuring the Frequency of Latent HIV-1 in Resting CD4+ T Cells Using a Limiting Dilution Coculture Assay. Methods in Molecular Biology, 2016, 1354, 239-253.	0.4	92
29	Recent developments in the search for a cure for HIV-1 infection: Targeting the latent reservoir for HIV-1. Journal of Allergy and Clinical Immunology, 2014, 134, 12-19.	1.5	88
30	HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. Journal of Clinical Investigation, 2018, 128, 3102-3115.	3.9	88
31	CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells. PLoS ONE, 2014, 9, e110731.	1.1	88
32	Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 223, 225-233.	1.9	80
33	Different human resting memory CD4 <sup>+</sup> T cell subsets show similar low inducibility of latent HIV-1 proviruses. Science Translational Medicine, 2020, 12, .	5.8	73
34	The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections. Cell Host and Microbe, 2019, 26, 73-85.e4.	5.1	71
35	Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy. Journal of Clinical Investigation, 2020, 130, 3543-3559.	3.9	69
36	The Remarkable Stability of the Latent Reservoir for HIV-1 in Resting Memory CD4 <sup>+</sup> T Cells. Journal of Infectious Diseases, 2015, 212, 1345-1347.	1.9	68

#	ARTICLE	IF	CITATIONS
37	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18692-18700.	3.3	67
38	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
39	A primary CD4+ T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. <i>Nature Protocols</i> , 2014, 9, 2755-2770.	5.5	46
40	Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	46
41	Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32066-32077.	3.3	44
42	The role of CD32 during HIV-1 infection. <i>Nature</i> , 2018, 561, E17-E19.	13.7	43
43	Recent trends in HIV-1 drug resistance. <i>Current Opinion in Virology</i> , 2013, 3, 487-494.	2.6	40
44	Engaging innate immunity in HIV-1 cure strategies. <i>Nature Reviews Immunology</i> , 2022, 22, 499-512.	10.6	39
45	Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells. <i>ELife</i> , 2016, 5, .	2.8	37
46	In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 271-294.	9.6	37
47	A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. <i>Annals of Internal Medicine</i> , 2022, 175, 95-100.	2.0	36
48	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e1973-e1981.	2.9	34
49	Assays to Measure Latency, Reservoirs, and Reactivation. <i>Current Topics in Microbiology and Immunology</i> , 2017, 417, 23-41.	0.7	31
50	Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure. <i>Journal of Infectious Diseases</i> , 2021, 223, S13-S21.	1.9	29
51	HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15763-15771.	3.3	28
52	Finding a Cure for Human Immunodeficiency Virus-1 Infection. <i>Infectious Disease Clinics of North America</i> , 2014, 28, 633-650.	1.9	22
53	Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. <i>PLoS Computational Biology</i> , 2019, 15, e1006849.	1.5	22
54	Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda. <i>Clinical Infectious Diseases</i> , 2017, 65, 1308-1315.	2.9	20

#	ARTICLE	IF	CITATIONS
55	Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions. <i>PLoS Pathogens</i> , 2016, 12, e1005679.	2.1	19
56	Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. <i>Journal of Infectious Diseases</i> , 2021, 224, 1209-1218.	1.9	18
57	Rekindled HIV infection. <i>Science</i> , 2014, 345, 1005-1006.	6.0	15
58	Nonsuppressible HIV-1 viremia: a reflection of how the reservoir persists. <i>Journal of Clinical Investigation</i> , 2020, 130, 5665-5667.	3.9	15
59	Similar Frequency and Inducibility of Intact Human Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. <i>Journal of Infectious Diseases</i> , 2020, 224, 258-268.	1.9	14
60	Biomarkers of HIV replication. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 491-497.	1.5	11
61	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. <i>Lancet HIV</i> , 2020, 7, e602-e610.	2.1	11
62	TCR-mimic bispecific antibodies to target the HIV-1 reservoir. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2123406119.	3.3	10
63	Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. <i>Journal of Infectious Diseases</i> , 2021, 223, 1905-1913.	1.9	8
64	Efforts to eliminate the latent reservoir in resting CD4+ T cells: strategies for curing HIV-1 infection. <i>Journal of Virus Eradication</i> , 2015, 1, 229-31.	0.3	4
65	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. <i>Npj Vaccines</i> , 2022, 7, 53.	2.9	4
66	108. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, S183-S183.	0.4	1
67	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 214.	1.5	0